Management of Pulmonary Embolism
The management of pulmonary embolism is fundamentally determined by risk stratification, with direct oral anticoagulants (DOACs) as first-line therapy for most patients, low-molecular-weight heparin (LMWH) preferred over unfractionated heparin for parenteral therapy, and systemic thrombolysis reserved exclusively for high-risk PE with hemodynamic instability. 1
Risk Stratification Framework
The 2026 AHA/ACC guidelines introduce a new clinical classification system (Categories A-E) that provides enhanced precision for treatment decisions 1:
- Category A (Asymptomatic): Safe for emergency department discharge without hospitalization
- Category B (Low severity, symptomatic): Eligible for early hospital discharge
- Category C (Elevated severity score): Includes elevated biomarkers and/or RV dysfunction; requires hospitalization
- Category D (Incipient cardiopulmonary failure): Requires hospitalization and consideration of advanced therapies
- Category E (Cardiopulmonary failure with persistent hypotension): High-risk PE requiring immediate advanced intervention
This aligns conceptually with the 2019 ESC framework of low-risk, intermediate-risk, and high-risk PE, though the AHA/ACC system provides more granular subcategories 2.
Anticoagulation Strategy
Initial Parenteral Therapy
For patients requiring parenteral anticoagulation, LMWH is recommended over unfractionated heparin (UFH) for most patients 1, 2. The ESC guidelines provide Level A evidence for this recommendation 2.
Key exception: UFH with weight-adjusted bolus is specifically recommended for high-risk PE (Category E) due to its rapid reversibility and titratability in hemodynamically unstable patients 2.
Oral Anticoagulation
DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) are recommended over vitamin K antagonists (VKAs) as first-line oral therapy 1, 2. This represents a Class I, Level A recommendation in both major guidelines.
Critical contraindications to DOACs 2:
- Severe renal impairment
- Pregnancy and lactation
- Antiphospholipid antibody syndrome (requires VKA indefinitely)
When VKAs are used, overlap with parenteral anticoagulation until INR reaches 2.5 (range 2.0-3.0) 2.
Duration of Anticoagulation
All patients require therapeutic anticoagulation for at least 3 months 2.
Extended anticoagulation beyond 3-6 months is recommended for 1:
- First PE without major reversible risk factor
- Persistent risk factors present
- Recurrent VTE (at least one previous PE or DVT episode)
Discontinue after 3 months only for: First PE secondary to major transient/reversible risk factor 2.
Advanced Therapies for High-Risk PE
Systemic Thrombolysis
Systemic thrombolytic therapy is recommended for high-risk PE (Category E1) with hemodynamic instability 1, 2. This is a Class I, Level B recommendation.
Critically important: Routine systemic thrombolysis is NOT recommended for intermediate- or low-risk PE (Class III, Level B) 2. The evidence shows thrombolysis in intermediate-risk disease reduces hemodynamic decompensation but increases major bleeding including intracranial hemorrhage, without demonstrating mortality benefit or long-term functional improvement 3.
Rescue Thrombolysis
Rescue thrombolytic therapy is recommended for patients with hemodynamic deterioration despite anticoagulation (Class I, Level B) 2.
Surgical and Catheter-Based Interventions
Surgical pulmonary embolectomy is recommended for high-risk PE when thrombolysis is contraindicated or has failed (Class I, Level C) 2.
Catheter-directed treatment should be considered for high-risk PE when thrombolysis is contraindicated or has failed (Class IIa, Level C) 2. The 2026 guidelines extend this consideration to Categories D1-2 (incipient cardiopulmonary failure) 1.
Important caveat: While recent trials like HI-PEITHO show ultrasound-facilitated catheter-directed thrombolysis may reduce decompensation in intermediate-high-risk patients, no survival benefit has been demonstrated, and the risk-benefit ratio remains unestablished for intermediate- or low-risk PE 3.
Hemodynamic Support
For high-risk PE, norepinephrine and/or dobutamine should be considered for hemodynamic support 2. ECMO may be considered in combination with surgical embolectomy or catheter-directed treatment for refractory circulatory collapse or cardiac arrest (Class IIb, Level C) 2.
Pulmonary Embolism Response Teams (PERTs)
PE response teams are recommended to improve timeliness of care 1. These multidisciplinary teams facilitate rapid decision-making for complex cases requiring advanced therapies.
Inferior Vena Cava Filters
IVC filters should be considered only for 2:
- Acute PE with absolute contraindications to anticoagulation (Class IIa, Level C)
- PE recurrence despite therapeutic anticoagulation (Class IIa, Level C)
Routine use of IVC filters is NOT recommended (Class III, Level A) 2.
Discharge and Outpatient Management
Asymptomatic patients (Category A) can be safely discharged from the emergency department without hospitalization 1.
Low-risk PE patients (Category B) should be considered for early discharge and home treatment if proper outpatient care and anticoagulation can be provided (Class IIa, Level A) 2.
Post-PE Follow-Up
Patients should be routinely re-evaluated 3-6 months after acute PE 1, 2. Screen for PE-related symptoms and functional limitations at every visit for at least 1 year to identify chronic thromboembolic pulmonary disease (CTEPD) or chronic thromboembolic pulmonary hypertension (CTEPH) 1, 2.
Refer symptomatic patients with mismatched perfusion defects on V/Q scan beyond 3 months to a pulmonary hypertension/CTEPH expert center, incorporating echocardiography, natriuretic peptides, and cardiopulmonary exercise testing results 2, 3. CTEPH develops in approximately 2-3% of PE survivors 3.
Common Pitfalls to Avoid
- Do not measure D-dimers in high clinical probability patients - normal results do not safely exclude PE (Class III) 2
- Do not perform CT venography as adjunct to CTPA (Class III) 2
- Do not use thrombolysis routinely in intermediate-risk PE - bleeding risks outweigh benefits without mortality improvement 2
- Do not use DOACs in pregnancy, severe renal impairment, or antiphospholipid syndrome 2
- Do not insert spinal/epidural needle within 24 hours of last LMWH dose in pregnant patients 2